VACCINATION WITH USING IMMUNO-ISOLATED CELLS PRODUCING IMMUNOMODULATOR Russian patent published in 2020 - IPC A61K39/00 A61K39/39 A61K9/48 

FIELD: medicine.

SUBSTANCE: group of inventions relates to a vaccine composition comprising: (a) at least one recoverable biocompatible macrocapsule, containing from approximately 1×10⁵ to approximately 1×10⁶ immuno-isolated allogenic cells of hematopoietic origin, secreting at least 20 ng/24 h of GM-CSF for at least 7 days, and (b) an antigenic component, where the antigen component contains 1×10⁶ to 1×10⁷ autologous tumor cells, obtained from a patient with chordoma, and where at least 4×10⁶ tumor cells are irradiated, where at least one biocompatible macrocapsule comprises: a core, containing allogenic cells and internal spiral having distance between coils of approximately 1 mm±0.1 mm, where allogenic cells are distributed on inner spiral; and semi-permeable membrane, surrounding the core, allowing diffusion of GM-CSF through it, and additionally contains one or several of the following: (i) extraction tube; (ii) extraction hook attached to extraction tube, where the extraction hook facilitates extraction of at least one biocompatible macrocapsule after implantation; (iii) connector, where the connector attaches a membrane of at least one biocompatible macrocapsule to the extraction tube; (iv) a loading connector, where the loading connector facilitates loading of cells, and (v) a test tube for transportation, wherein a test tube for transportation comprises a test tube body and a test tube lid, wherein said composition is intended for treating a malignant tumor selected from a group consisting of lung cancer, melanoma, breast cancer, colon cancer, pancreatic cancer, kidney cancer, acute leukemia, chronic leukemia, glioblastoma, low-grade lymphoma, high-grade lymphoma, multiple myeloma, sarcoma, bone malignant tumor, cerebral tumors, stomach cancer, oesophageal cancer, head and neck cancer, thyroid cancer, bladder cancer, prostate cancer, ovarian cancer, uterine body cancer, chordoma and cervical cancer, or for therapeutic or preventive vaccination, also relates to a pharmaceutical composition comprising a vaccine composition and a physiologically acceptable carrier, also relates to a method of treating or vaccinating malignant tumors, also relates to a method of producing at least one biocompatible macrocapsule used in a vaccine composition, involving: (a) culturing allogenic cells for at least two passages to ensure that the cells secrete GM-CSF; (b) resuspending cultured cells in a cell culture medium; (c) loading cells into at least one biocompatible macrocapsule through a loading connector; and (d) cutting the extraction tube to remove the loading connector.

EFFECT: group of inventions consists in preparing the vaccine compositions providing both a constant immunomodulatory source, and antigen component, which are mainly free from undesirable interactions with natural or adaptive immune system.

42 cl, 6 ex, 11 dwg